Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs (Q33331450)

25 July 2017

title

Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs (English)

1 reference

25 July 2017

1 reference

Degui Wang

1

1 reference

25 July 2017

Zhiping Wang

2

1 reference

25 July 2017

Binqiang Tian

3

1 reference

25 July 2017

Xiaoming Li

4

1 reference

25 July 2017

Shigang Li

5

1 reference

25 July 2017

Yingxia Tian

6

1 reference

25 July 2017

publication date

1 May 2008

1 reference

International Journal of Urology

25 July 2017

published in

1 reference

25 July 2017

volume

15

1 reference

25 July 2017

issue

5

1 reference

25 July 2017

page(s)

435-441

1 reference

Class II histone deacetylases: versatile regulators

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Sodium butyrate induces apoptosis and cell cycle arrest in primary effusion lymphoma cells independently of oxidative stress and p21(CIP1/WAF1) induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02025.X

10.1111/J.1442-2042.2008.02025.X

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference